An affiliate of Aterian Investment Partners, a private investment firm, has agreed to recapitalize Contract Pharmaceuticals Limited Canada (CPL), a North American contract development and manufacturing organization (CDMO) of non-sterile liquid and semi-solid dosage forms.
 
CPL, based in Mississauga, Ontario, Canada, boasts longstanding relationships with 15 of the top 20 global pharmaceutical companies. The company supports its customers through its FDA and Health Canada-registered facilities, selling into North America, the European Union, Japan, Australia, Mexico, Brazil, and the Middle East.
 
Christopher H. Thomas, Co-Founder & Partner at Aterian, stated, “CPL is a North American market leader in developing prescription-based products in its categories for some of the most trusted pharmaceutical companies in the world. We will continue building on these partnerships and investing behind the CPL management team, product development, and production and manufacturing capabilities.”
 
“We are very excited to enter this new chapter with Aterian, which has a demonstrated history of supporting companies with a focus on product innovation and partnership,” said Jan Sahai, CEO of CPL. “With Aterian’s support, we will make continued investments in innovation, capabilities and capacity development that will enable us to keep exceeding customer expectations and further expand our unmatched position in the non-sterile liquid and topical drug products space. I want also to acknowledge the absolute dedication of CPL employees during this process to continue to develop and manufacture products so many patients are depending on.”
 
The proposed recapitalization is subject to the approval of the Ontario Superior Court of Justice (Commercial List).